In-Silico Investigation of GRP78 Inhibition in Glioblastoma: Implications for Therapeutic Targeting | ||
| Sohag Journal of Sciences | ||
| Volume 10, Issue 2, June 2025, Pages 266-273 PDF (763.93 K) | ||
| Document Type: Regular Articles | ||
| DOI: 10.21608/sjsci.2025.367748.1262 | ||
| Authors | ||
| Mahmoud E. Rashwan* 1; Mahrous R. Ahmed1; Abdo A. Elfiky2 | ||
| 1Physics Department, Faculty of Science, Sohag University, Sohag, 82524, Egypt | ||
| 2Biophysics Department, Faculty of Science, Cairo University, Giza, 12613, Egypt | ||
| Abstract | ||
| Glioblastoma (GBM) is an aggressive, fast-growing, and treatment-resistant tumor with high recurrence and poor prognosis. GRP78 is a molecular chaperone implicated in cancer cell survival, proliferation, and stress response, and overexpression has been shown to play a role in GBM development and drug resistance. In this work, we examine Zidovudine triphosphate (ZDV-TP) as a potential GRP78 inhibitor by computational approaches, including molecular docking, molecular dynamics (MD) simulations, and MMGBSA calculations. The results indicate that ZDV-TP securely binds to and energetically favors the ATP-binding site of GRP78, suggesting that it could disrupt its chaperone function. 100 ns MD simulations show that the GRP78-ZDV-TP complex is stable without significant conformational change, implying no destabilization of the protein structure. Such findings form a foundation that ZDV-TP is effective in inhibiting GRP78 and can abolish its role in GBM tumor formation and drug resistance. Further experimental proof should be tested for ZDV-TP to be an auspicious therapeutic target of GBM. | ||
| Keywords | ||
| GRP78; glioblastoma; molecular dynamics simulation; molecular docking; binding energy calculation | ||
|
Statistics Article View: 193 PDF Download: 139 |
||
